Clinical trial Recruiting at 1 site Interventional Ages 7 to 20

Noninvasive vagus nerve stimulation for prevention and treatment of primary headaches in children and teens

Official title: Noninvasive Vagus Nerve Stimulation for the Prevention and Treatment of Primary Headache: a Single-arm Single-center Clinical Trial.

Run by Nanfang Hospital, Southern Medical University · NCT06277063 · Data updated 2026-11-12

We will try a noninvasive ear-based vagus nerve stimulator to treat sudden primary headache attacks in children and adolescents aged 7–20.

More Cluster Headache trials

Quick facts

Study typeInterventional
Ages7 Years to 20 Years
SexAll
Enrollment15 (estimated)
SponsorNanfang Hospital, Southern Medical University
Academic / other
Locations1 site (Guangzhou, Guangdong)
StatusRecruiting
StartedDecember 5, 2024
Main results expectedAugust 31, 2026
Study endsDecember 30, 2026
Registry record updatedAugust 12, 2025
Trial IDNCT06277063 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Children and adolescents 7–20 years old with diagnosed primary headaches (migraine, cluster, or tension-type) who experience 3–15 headache days per month and keep medications stable are ideal candidates.

Probably not a fit

Patients with secondary headaches, a history of seizures, implanted electronic devices, or those unable to attend in-person visits are unlikely to benefit or be eligible.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center, single-arm study enrolls participants aged 7–20 with primary headaches and applies transcutaneous auricular vagus nerve stimulation (nVNS) during acute exacerbations. Each subject receives the same short-duration stimulation with the electrode placed on the concha and stimulation intensity adjusted individually. Headache scores before and after the intervention will be compared to measure acute symptom change, and concurrent ECG and EMG data will be collected to develop objective response markers. Participants must have 3–15 headache days per month and maintain stable medication regimens during the study.

Why it matters

Potential benefit: If successful, the device could offer a quick, non-drug option to reduce the intensity of acute headache attacks in children and adolescents.

How similar studies have gone: Similar nVNS approaches have shown promising but mixed results for acute migraine and cluster headache in adults, while pediatric evidence is limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Patients with migraine, cluster headache and tension-type headache were diagnosed according to Chinese Guidelines for the diagnosis and Treatment of Migraine (2022 edition) and Chinese Guidelines for the diagnosis and treatment of cluster headache (2022 edition).
2. Age \>=7 years old, \<=20 years old;
3. Patients have experienced headache on 3-15 days per month in the past;
4. Maintain a stable dose and frequency of medication and do not take new drugs during the course of participating in the trial;
5. They volunteered to participate in the trial and signed informed consent.

Exclusion Criteria:

1. History of secondary headache, aneurysm, intracranial hemorrhage, brain tumor, severe head trauma, drug abuse, addiction, syncope, or seizures;
2. prior migraine-preventive surgery, cervical vagotomy, or implantation of an electronic or neurostimulator device;
3. Simultaneous use of other devices (e.g., TENS devices, muscle stimulators);
4. An implantable medical device in use, such as a pacemaker, hearing aid, or any implantable electronic device;
5. underwent head and neck nerve block within the past 2 months;
6. Opioid use (more than 2 days per month); Use of analgesics alone or non-steroidal anti-inflammatory drugs (more than 15 days per month); Or tamoxifen, ergots or combination analgesics (more than 10 days per month);
7. Patients who underwent cervical vagotomy (cervical vagotomy);
8. Pediatric patients (under 6 years old); Pregnant women;
9. Patients with clinically significant hypertension, hypotension, bradycardia or tachycardia;
10. Patients with congenital heart disease;
11. Mental/cognitive disorders, etc.

Where it's running

  • Nanfang Hospital, Southern Medical University
    Guangzhou, Guangdong, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.